Thomas W. Samuelson, MD

NEW YORK — In this presentation from OSN New York, Thomas W. Samuelson, MD, of Minnesota Eye Consultants, uses surgical footage to demonstrate implantation of the Xen gel stent for the treatment of glaucoma.

NEW YORK — In this Healio Video Perspective from OSN New York, Thomas W. Samuelson, MD, overviews trending topics in the glaucoma space, including challenges amid technician shortages and interventional approaches to treatment.

KIAWAH ISLAND, S.C. — In a presentation from Kiawah Eye, Thomas W. Samuelson, MD, discusses data supporting laser therapy as the first option for glaucoma treatment and upcoming laser technology.

SAN DIEGO — In this Healio Video Perspective from Eyecelerator@ASCRS, Thomas W. Samuelson, MD, discusses 2-year data from the first-in-human study investigating femtosecond laser technology in glaucoma surgery.

In this Healio Video Perspective from the American Glaucoma Society meeting, Thomas W. Samuelson, MD, discusses positive safety and efficacy data for the ViaLase femtosecond laser image-guided high-precision trabeculotomy treatment.

WAILEA, Hawaii — In this video from Hawaiian Eye, Thomas W. Samuelson, MD, discusses the nuanced decision-making that goes into deciding which surgical interventions to use in patients with glaucoma who are also in need of cataract surgery.

In this Healio Video Perspective from the virtual AAO annual meeting, Thomas W. Samuelson, MD, summarizes results from the 3-year pivotal trial of the iStent inject (Glaukos).

NEW YORK — During his presentation at OSN New York 2019, Thomas W. Samuelson, MD, discusses surgical treatment options for glaucoma and when each is ideal.

KIAWAH ISLAND, S.C. — At the Kiawah Eye meeting here, Thomas W. Samuelson, MD, discusses the latest advancements in MIGS, reviewing the procedures through stage of disease and degree of disruption.

KIAWAH ISLAND, S.C. — At the Kiawah Eye meeting here, Thomas W. Samuelson, MD, discusses the strengths and weaknesses of the new MIGS devices on the U.S. market, including the iStent inject (Glaukos), Hydrus (Ivantis), Xen (Allergan) and Omni (Sight Sciences) devices.